$3.23
0.12[3.86%]
At close: May 21
$3.23
0[0.00%]
PreMarket: 4:00PM EDT
Galectin Therapeutics
(NASDAQ:GALT)Latest News for Galectin Therapeutics Stock (NASDAQ:GALT)
Galectin Therapeutics Stock (NASDAQ: GALT)
Categories: All
Wednesday, May 15, 2024
- As Of March 31, 2024, Galectin Therapeutics Had $23.6M Of Cash And Cash Equivalents. Additionally, The Company Has $10M Remaining Available Under A $60M Line Of Credit Expected To Provide Cash Runway Into May 2025Benzinga Newsdesk - May 15, 2024, 8:02AM
- Galectin Therapeutics Q1 2024 GAAP EPS $(0.19) Misses $(0.16) EstimateBenzinga Newsdesk - May 15, 2024, 7:58AM
Tuesday, April 23, 2024
Tuesday, April 09, 2024
Friday, April 05, 2024
Monday, April 01, 2024
Monday, November 13, 2023
- Galectin Therapeutics: Q3 Earnings InsightsBenzinga Insights - Nov 13, 2023, 8:50AM
- Galectin Therapeutics' $20.4M Of Cash And Cash Equivalents And $30M Remaining Available Under A $60M Line Of Credit Provided By Its Chairman Is Sufficient Cash To Fund Currently Planned Operations And R&D Activities Through At Least December 31, 2024Benzinga Newsdesk - Nov 13, 2023, 8:23AM
- Galectin Therapeutics Q3 EPS $(0.24) Misses $(0.16) Estimate;Benzinga Newsdesk - Nov 13, 2023, 8:23AM
Tuesday, September 26, 2023
Tuesday, August 15, 2023
Monday, August 14, 2023
Friday, July 21, 2023
Wednesday, May 17, 2023
Thursday, March 30, 2023
Friday, March 03, 2023
Wednesday, February 22, 2023
Tuesday, February 07, 2023
Tuesday, January 24, 2023
Thursday, January 05, 2023
Monday, November 14, 2022
Wednesday, October 12, 2022
Thursday, September 29, 2022
Monday, August 15, 2022
Monday, August 01, 2022
Friday, July 29, 2022
Wednesday, July 27, 2022
Tuesday, June 21, 2022
Thursday, June 02, 2022
Tuesday, May 24, 2022
Tuesday, May 17, 2022
Monday, May 16, 2022
Wednesday, May 11, 2022
Wednesday, May 04, 2022
Thursday, April 28, 2022
Thursday, April 14, 2022
- 12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga Insights - Apr 14, 2022, 5:48PM
- Galectin Therapeutics Reports Outcome Of The First Data And Safety Monitoring Board For NAVIGATE, Its Seamless, Adaptive Phase 2b/3 Study Of Belapectin In Patients With Liver Cirrhosis Caused By Non-Alcoholic SteatohepatitisBenzinga Newsdesk - Apr 14, 2022, 7:54AM